Kansenshogaku Zasshi
Online ISSN : 1884-569X
Print ISSN : 0387-5911
ISSN-L : 0387-5911
Double-Blind Comparative Clinical Study of Cefpiramide (SM-1652) and Cefmetazole in Complicated Urinary Tract Infections
Joji ISHIGAMI, Sadao KAMIDONO, Sohichi ARAKAWA, Nobumasa KATAOKA, Koji NAKANO, Masuyoshi HARADA, Kyubei HIROOKA, Nobori SHIMATANI, Atsushi ITANI, Masami MATSUSHITA, Koji HIKOSAKA, Osamu MATSUMOTO, Kakuyoshi OHYA, Noboru ITO, Kenji HARADA, Toshikazu KIYOTA, Hiroshi SAITO, Yoshihiko KITANO, Yasumasa TAKAHASHI, Shinji HARA, Hiroshi OHMAE, Toru OHBE, Hirohiko YASUNO, Nobuo KATAOKA, Hiroshi OKUDAIRA, Gaku KAWABATA, Hideo OHSHIMA, Shusoo DEN, Osamu TOMIOKA, Shigenori TADERA, Hiroshi UEHARAGUCHI, Yoshinori ODA, Hiroshi YAMAZAKI, Kenichi TAKADA, Yasunaga OKADA, Suguru HINENO, Yasuji KURODA, Shunro MOMOSE, Mineo TAKEI, Joichi KUMAZAWA, Seiichi NAKAMUTA, Kimitaka SAKAMOTO, Kazuhiro OSHIMA, Nobuyuki ISHIZAWA, Yukio OSADA, Sanshin HARA, Kanichi EMOTO, Kozo HIRATA, Ichikiro MORITA, Kunihiro MINODA, Haruka HIRANO, Hiroyuki NAGAYOSHI, Shinichi SATO, Tetsuo OMOTO, Hiroaki YAGI, Hiroshi HIRATA, Sadamu ANDO, Eiji IWATSUBO, Shinichiro KOMINE, Nobuya OGAWA
Author information
Keywords: Cefpiramide (CPM, SM-1652), A new cephem antibiotics, Urinary tract infection, Double-blind comparative study
JOURNAL FREE ACCESS

1983 Volume 57 Issue 8 Pages 695-723

Details
Download PDF (2779K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

The clinical efficacy and safety of cefpiramide (SM-1652, CPM) were compared with those of cefmetazole (CMZ) in patients with complicated urinary tract infections by double-blind method.
Either of CPM or CMZ was assigned to each patient at random. Administration was performed by intravenous drip infusion for a fixed period of 5 days and daily dosage was fixed at each 2 g for CPM or CMZ.
Out of 249 patients, 211 patients (CPM; 110 cases, CMZ: 101 cases) were evaluated for clinical efficacy by the criteria proposed by UTI committee in Japan. It was indicated that there was no significant difference between the two groups (CPM group and CMZ group) regarding the all of background factors.
Overall clinical effectiveness; Response was excellent in 27.7%, moderate in 39.8% and poor in 32.5% of the CPM group, excellent in 17.3%, moderate in 33.3% and poor in 49.3% of the CMZ group. Response rate inclusive of excellent and moderate was significantly higher in the CPM group than in the CMZ (p<0.05).
Effect on pyuria; Rate of improvement (Cleared and Decreased) on pyuria was 44.6% in the CPM group and 36.0% in the CMZ group. There was no significant difference between the two groups.
Effect on bacteriuria; Rate of improvement (Eliminated and Decreased) on bacteriuria was 60.2% in the CPM group and 46.7% in the CMZ group. There was no significant difference between the two groups.
Bacteriological response; The eradication rate for all organisms isolated before treatment was 75.8% in the CPM group and 80.2% in the CMZ group. There was no significant difference between the two groups.
The incidence rate of side effects and abnormal laboratory findings were 2 cases (eruption 2) and 3 cases (elevation of transaminase), respectively in the CPM group and 1 case (itching and pericheiloparalysis) and 4 cases (elevation of transaminase or BUN), respectively in the CMZ group, with no significant differences between the two groups.
These results indicate that CPM is a useful drug for the treatment of complicated urinary tract infections.

Content from these authors
© The Japansese Association for Infectious Diseases
Previous article Next article
Favorites & Alerts

Recently viewed articles
Predecessor

Journal of the Japanese Association for Infectious Diseases

Share this page
feedback
 Top